Get Updates

Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More


A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Study identifier: NCT01749397
Full study details on

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)


Metastatic epithelial ovarian, primary peritoneal, or fallopian tube cancer for which standard curative measures do not exist, no prior PARP inhibitor.

Type of study:

Phase I study


21-day cycles with veliparib intravenously on days 1-10 and floxuridine intraperitoneal on days 3-5

Study sites:

Johns Hopkins University
Contact: Deborah K. Armstrong 410-955-8804
Principal Investigator: Deborah K. Armstrong

Mayo Clinic
Contact: Andrea E. Wahner Hendrickson 507-284-2511

Page updated 06/13/13

FORCE:Facing Our Risk of Cancer Empowered